Item Detail

Completely revised and updated, the 3rd Edition of this premier resource provides cutting-edge coverage of the epidemiology, immunology, and hematology of myelomaall in one convenient reference. A team of leading international authorities in myeloma research presents a worldwide perspective on the most recent developments in management and therapeutic options, as well as the latest clinical understanding of the disease.

• Covers epidemiology, immunology, and hematology of myeloma all in a one-stop resource.

• Provides new information on the biology, staging, and treatment of myeloma.
• Offers new chapters on cytogenetics of multiple myeloma, molecular profiling of myeloma, prognostic factors, and novel agents for multiple myeloma, including those targeting tumors and microenvironment.
• Presents the most recent breakthroughs in treatment, including various new drugs of proven efficacy such as Proteasome inhibitor Bortezomib, immunomodulatory drug Revamid, and controversial thalidomide, as well as treatment options just on the horizon.
• Includes up-to-date information on gene micro-array profiling studies, which impact myeloma pathogenesis and identify targets of sensitivity versus resistance to new therapies.